PMID- 22882940
OWN - NLM
STAT- MEDLINE
DCOM- 20130102
LR  - 20161125
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 14
DP  - 2012 Jul
TI  - In vivo administration of Fms-like tyrosine kinase-3 ligand effectively 
      stimulates lung dendritic cell expansion in mice.
PG  - 2562-7
AB  - BACKGROUND: Dendritic cells (DCs) are the most important professional antigen 
      presenting cells that play a key role in initiating adaptive immune responses. 
      The depletion and dysfunction of DCs contribute to the development of 
      immunodeficiency or immunoparalysis in some lung diseases. In the present study, 
      we investigated the effects of Fms-like tyrosine kinase-3 ligand (Flt3L) 
      administration in vivo on lung DCs expansion to provide an experimental basis of 
      Flt3L used as a potential therapeutic agent for the related lung disorders. 
      METHODS: Balb/c mice were randomly divided into Flt3L group (n = 10) and control 
      group (n = 10). Each mouse in the Flt3L group received subcutaneous 
      administration of Flt3L at a dose of 10 microg once daily for nine consecutive days. 
      Lung histology was observed, and CD11c and CD205 were immunologically labeled in 
      lung tissue sections. Low-density lung cells were separated by density gradient 
      centrifugation, and then subsets and MHC-II/I-A(d) expression of DCs were 
      analyzed by flow cytometry. RESULTS: In the Flt3L group the number and density of 
      DC-like cells were markedly increased compared with the control group, mainly 
      distributed in the alveolar septa. Immunological labeling in situ found that 
      there were significantly higher numbers of CD11c(+) and CD205(+) DCs in lung 
      mesenchymal tissue (P < 0.05), where they formed a denser reticular formation. 
      Flow cytometry analysis demonstrated that the proportions of myeloid 
      CD11c(+)CD11b(+) DCs and plasmacytoid CD11c(+)CD45R/B220(+) DCs in the 
      low-density lung cells in the Flt3L group were significantly higher compared with 
      the control group; showing 3.17- and 3.3-fold increase respectively (P < 0.05). 
      The proportion of CD11c(+) DCs expressing MHC-II/I-A(d+) was significantly 
      increased, with a 2.7-fold increase as compared with the control group (P < 
      0.05). CONCLUSIONS: Flt3L administration in vivo induces lung DCs expansion, 
      favoring myeloid and plasmacytoid DC subsets, which are phenotypically more 
      mature. Flt3L may be useful in the therapy to augment immune function of the 
      lung.
FAU - Wang, Hong-Wei
AU  - Wang HW
AD  - Department of Pathology, First Affiliated Hospital of General Hospital of 
      People's Liberation Army, Beijing 100048, China.
FAU - Lu, Jiang-Yang
AU  - Lu JY
FAU - Wang, Lin
AU  - Wang L
FAU - Tian, Guang
AU  - Tian G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Antigens, CD)
RN  - 0 (DEC-205 receptor)
RN  - 0 (Lectins, C-Type)
RN  - 0 (Membrane Proteins)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (flt3 ligand protein)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Cells, Cultured
MH  - Dendritic Cells/*drug effects/metabolism/ultrastructure
MH  - Flow Cytometry
MH  - Immunohistochemistry
MH  - Lectins, C-Type/metabolism
MH  - Lung/*drug effects/metabolism/ultrastructure
MH  - Male
MH  - Membrane Proteins/*pharmacology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microscopy, Electron, Transmission
MH  - Minor Histocompatibility Antigens
MH  - Random Allocation
MH  - Receptors, Cell Surface/metabolism
EDAT- 2012/08/14 06:00
MHDA- 2013/01/03 06:00
CRDT- 2012/08/14 06:00
PHST- 2012/08/14 06:00 [entrez]
PHST- 2012/08/14 06:00 [pubmed]
PHST- 2013/01/03 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Jul;125(14):2562-7.